Cycloheptanol, 2,2,7,7-tetramethyl-1-(2-propenyl)-
Common Name: |
Cycloheptanol, 2,2,7,7-tetramethyl-1-(2-propenyl)- |
IUPAC Name: |
2,2,7,7-tetramethyl-1-prop-2-enylcycloheptan-1-ol |
Molecular Formula: |
C14H26O |
SMILES: |
CC1(CCCCC(C1(CC=C)O)(C)C)C |
Inchi: |
1S/C14H26O/c1-6-9-14(15)12(2,3)10-7-8-11-13(14,4)5/h6,15H,1,7-11H2,2-5H3 |
Inchi Key: |
FFYUAKBJWFOMLK-UHFFFAOYSA-N |
Cas No: |
105463-44-3 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
0 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
210.36 |
Mass (g/mol) |
210.198 |
Molar Refractivity |
67.50 |
Net Charge |
|
HBD |
1 |
HBA |
1 |
Rt Bonds |
2 |
Rings |
1 |
TPSA |
20.23 |
Hetero Atoms |
1 |
Heavy Atoms |
15 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
198.00 to 200.00 @ 111.00 mm Hg |
Vapor Pressure (mmHg@25.00 °C) |
0.002 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.86 |
LogP |
3.92 |
iLOGP |
3.02 |
XLOGP3 |
4.48 |
WLOGP |
3.92 |
MLOGP |
3.41 |
ESOL Log S |
-3.83 |
ESOL Solubility (mg/ml) |
0.031 |
ESOL Solubility (mol/l) |
0 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-4.62 |
Ali Solubility (mg/ml) |
0 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Moderately soluble |
Silicos-IT LogSw |
-3.62 |
Silicos-IT Solubility (mg/ml) |
0.05 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-4.40 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.447 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
2.765 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
1 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |